{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:06:20Z","timestamp":1750910780893,"version":"3.41.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IUDB\/004462\/2020\/TL2\/P2","UIDB\/00100\/2020","UIDP\/00100\/2020","LA\/P\/0056\/2020","PTDC\/MED-TOX\/30418\/2017","2022.06292.PTDC","RNEM-LISBOA-01-0145-FEDER-022125","2022.11188.BD","PD\/BD\/114257\/2016","SFRH\/BD\/131331\/2017","UIDP\/04462\/2020"],"award-info":[{"award-number":["IUDB\/004462\/2020\/TL2\/P2","UIDB\/00100\/2020","UIDP\/00100\/2020","LA\/P\/0056\/2020","PTDC\/MED-TOX\/30418\/2017","2022.06292.PTDC","RNEM-LISBOA-01-0145-FEDER-022125","2022.11188.BD","PD\/BD\/114257\/2016","SFRH\/BD\/131331\/2017","UIDP\/04462\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005855","name":"Universidade Nova de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005855","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We were pioneers in describing aryl hydrocarbon receptor (AhR) activation by chronic intermittent hypoxia (CIH) in a rat pre-clinical model. This model mimics hypertension (HTN) secondary to obstructive sleep apnea, enabling longitudinal investigation of hypertension development. Concerns about the influence of barbiturates on AhR-regulated enzymes led us to opt for ketamine\/medetomidine anesthesia in terminal in vivo experiments. However, the biotransformation and the metabolomic pathways of ketamine in CIH conditions, which is associated to AhR overactivation, are yet to be disclosed. A rat model of CIH was used, with experimental groups defined based on the duration of CIH exposure. Ketamine\/medetomidine (75\/0.5 mg\/kg) was administered intraperitoneally as terminal anesthetic. Metabolomic strategies were used to reveal the profiles of ketamine and its metabolites in liver and kidney tissues, uncovering six metabolites, including the first report of norketamine glucuronide formation in the liver. While PCA analysis revealed similar ketamine metabolite fingerprints in normoxia and CIH, a predominance of hydroxynorketamine over norketamine was observed in CIH condition. A consistent association between norketamine, hydroxyketamine and the metabolome was found in both normoxia and CIH conditions. The AhR antagonist CH-223191 (5 mg\/kg) influenced hydroxynorketamine glucuronidation in the liver. No changes in medetomidine biotransformation were detected. Overall, these findings expand the knowledge of ketamine metabolism and its tissue-dependence. The results emphasize the importance of considering how ketamine biotransformation may differ between control and experimental conditions in metabolic studies, particularly in chronic intermittent hypoxia conditions. The role of AhR in ketamine biotransformation is herein described for the first time.<\/jats:p>","DOI":"10.1007\/s00204-025-04044-w","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T18:34:01Z","timestamp":1745087641000},"page":"2835-2844","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biotransformation of ketamine in terminal in vivo experiments under chronic intermittent hypoxia conditions and the role of AhR"],"prefix":"10.1007","volume":"99","author":[{"given":"Ant\u00f3nio B.","family":"Pimp\u00e3o","sequence":"first","affiliation":[]},{"given":"Lu\u00edsa","family":"Teixeira-Santos","sequence":"additional","affiliation":[]},{"given":"Nuno R.","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Maria Jo\u00e3o","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Judit","family":"Morello","sequence":"additional","affiliation":[]},{"given":"Alexandra M. M.","family":"Antunes","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia C.","family":"Monteiro","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-9995","authenticated-orcid":false,"given":"Sofia A.","family":"Pereira","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,4,19]]},"reference":[{"key":"4044_CR1","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.4088\/JCP.17F11738","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C (2017) Ketamine for depression, 4. In what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry 78:e852\u2013e857. https:\/\/doi.org\/10.4088\/JCP.17F11738","journal-title":"J Clin Psychiatry"},{"key":"4044_CR2","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1113\/JP284166","volume":"601","author":"C Arnaud","year":"2023","unstructured":"Arnaud C, Billoir E, de Melo Junior AF et al (2023) Chronic intermittent hypoxia-induced cardiovascular and renal dysfunction: from adaptation to maladaptation. J Physiol 601:5553\u20135577. https:\/\/doi.org\/10.1113\/JP284166","journal-title":"J Physiol"},{"key":"4044_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/S00204-016-1700-4","volume":"91","author":"EA Attignon","year":"2017","unstructured":"Attignon EA, Leblanc AF, Le-Grand B et al (2017) Novel roles for AhR and ARNT in the regulation of alcohol dehydrogenases in human hepatic cells. Arch Toxicol 91:313\u2013324. https:\/\/doi.org\/10.1007\/S00204-016-1700-4","journal-title":"Arch Toxicol"},{"key":"4044_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/S00044-023-03062-6\/METRICS","volume":"32","author":"TA Baillie","year":"2023","unstructured":"Baillie TA (2023) Acyl glucuronides\u2013mediators of drug-induced toxicities? Med Chem Res 32:1249\u20131262. https:\/\/doi.org\/10.1007\/S00044-023-03062-6\/METRICS","journal-title":"Med Chem Res"},{"key":"4044_CR5","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/J.JNUTBIO.2013.08.009","volume":"24","author":"NA Baker","year":"2013","unstructured":"Baker NA, English V, Sunkara M et al (2013a) Resveratrol protects against polychlorinated biphenyl-mediated impairment of glucose homeostasis in adipocytes. J Nutr Biochem 24:2168\u20132174. https:\/\/doi.org\/10.1016\/J.JNUTBIO.2013.08.009","journal-title":"J Nutr Biochem"},{"key":"4044_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1289\/EHP.1205421","volume":"121","author":"NA Baker","year":"2013","unstructured":"Baker NA, Karounos M, English V et al (2013b) Coplanar polychlorinated biphenyls impair glucose homeostasis in lean C57BL\/6 mice and mitigate beneficial effects of weight loss on glucose homeostasis in obese mice. Environ Health Perspect 121:110. https:\/\/doi.org\/10.1289\/EHP.1205421","journal-title":"Environ Health Perspect"},{"key":"4044_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/JMS.1963","volume":"46","author":"L Bijlsma","year":"2011","unstructured":"Bijlsma L, Sancho JV, Hern\u00e1ndez F, Niessen WMA (2011) Fragmentation pathways of drugs of abuse and their metabolites based on QTOF MS\/MS and MS(E) accurate-mass spectra. J Mass Spectrom 46:865\u2013875. https:\/\/doi.org\/10.1002\/JMS.1963","journal-title":"J Mass Spectrom"},{"key":"4044_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/nbt.2377","volume":"30","author":"MC Chambers","year":"2012","unstructured":"Chambers MC, MacLean B, Burke R et al (2012) A cross-platform toolkit for mass spectrometry and proteomics. Nat Biotechnol 30:918\u2013920. https:\/\/doi.org\/10.1038\/nbt.2377","journal-title":"Nat Biotechnol"},{"key":"4044_CR9","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1080\/15287390590967522","volume":"68","author":"WH Chan","year":"2005","unstructured":"Chan WH, Sun WZ, Ueng TH (2005) Induction of rat hepatic cytochrome P-450 by ketamine and its toxicological implications. J Toxicol Environ Health 68:1581\u20131597. https:\/\/doi.org\/10.1080\/15287390590967522","journal-title":"J Toxicol Environ Health"},{"key":"4044_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1875-4597(08)60013-2","volume":"46","author":"WH Chan","year":"2008","unstructured":"Chan WH, Su HC, Hung MH et al (2008) Induction of hepatic glutathione S-transferase and UDP-glucuronosyltransferase activities by ketamine in rats. Acta Anaesthesiol Taiwan 46:2\u20137. https:\/\/doi.org\/10.1016\/S1875-4597(08)60013-2","journal-title":"Acta Anaesthesiol Taiwan"},{"key":"4044_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/DMD.108.023325","volume":"37","author":"HC Chang","year":"2009","unstructured":"Chang HC, Chen TL, Chen RM (2009) Cytoskeleton interruption in human hepatoma HepG2 cells induced by ketamine occurs possibly through suppression of calcium mobilization and mitochondrial function. Drug Metab Dispos 37:24\u201331. https:\/\/doi.org\/10.1124\/DMD.108.023325","journal-title":"Drug Metab Dispos"},{"key":"4044_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2020.104869","volume":"159","author":"NR Coelho","year":"2020","unstructured":"Coelho NR, Tomkiewicz C, Correia MJ et al (2020) First evidence of aryl hydrocarbon receptor as a druggable target in hypertension induced by chronic intermittent hypoxia. Pharmacol Res 159:104869. https:\/\/doi.org\/10.1016\/J.PHRS.2020.104869","journal-title":"Pharmacol Res"},{"key":"4044_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/J.PHRS.2020.105407","volume":"165","author":"NR Coelho","year":"2021","unstructured":"Coelho NR, Matos C, Pimp\u00e3o AB et al (2021) AHR canonical pathway: in vivo findings to support novel antihypertensive strategies. Pharmacol Res 165:105407. https:\/\/doi.org\/10.1016\/J.PHRS.2020.105407","journal-title":"Pharmacol Res"},{"key":"4044_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/S00109-021-02163-2","volume":"100","author":"NR Coelho","year":"2022","unstructured":"Coelho NR, Pimp\u00e3o AB, Correia MJ et al (2022) Pharmacological blockage of the AHR-CYP1A1 axis: a call for in vivo evidence. J Mol Med (Berl) 100:243. https:\/\/doi.org\/10.1007\/S00109-021-02163-2","journal-title":"J Mol Med (Berl)"},{"key":"4044_CR15","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3390\/ANTIOX10091484","volume":"10","author":"MJ Correia","year":"2021","unstructured":"Correia MJ, Pimp\u00e3o AB, Lopes-Coelho F et al (2021) Aryl Hydrocarbon receptor and cysteine redox dynamics underlie (mal)adaptive mechanisms to chronic intermittent hypoxia in kidney cortex. Antioxidants 10:1484. https:\/\/doi.org\/10.3390\/ANTIOX10091484","journal-title":"Antioxidants"},{"key":"4044_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1590\/S0102-86502011000300008","volume":"26","author":"FG Curtis","year":"2011","unstructured":"Curtis FG, Vianna PTG, Viero RM et al (2011) Dexmedetomidine and S(+)-ketamine in ischemia and reperfusion injury in the rat kidney. Acta Cir Bras 26:202\u2013206. https:\/\/doi.org\/10.1590\/S0102-86502011000300008","journal-title":"Acta Cir Bras"},{"issue":"9","key":"4044_CR52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","volume":"76","author":"EJ Daly","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, Lane R, Lim P, Duca AR, Hough D, Thase ME, Zajecka J, Winokur A, Divacka I, Fagiolini A, Cubala WJ, Bitter I, Blier P, Shelton RC, Molero P, Manji H, Drevets WC, Singh JB (2019) Efficacy of Esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 76(9):893\u2013903. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1189","journal-title":"JAMA Psychiatry"},{"key":"4044_CR17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1165\/RCMB.2017-0260OC\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"58","author":"A Dean","year":"2018","unstructured":"Dean A, Gregorc T, Docherty CK et al (2018) Role of the aryl hydrocarbon receptor in sugen 5416-induced experimental pulmonary hypertension. Am J Respir Cell Mol Biol 58:320\u2013330. https:\/\/doi.org\/10.1165\/RCMB.2017-0260OC\/SUPPL_FILE\/DISCLOSURES.PDF","journal-title":"Am J Respir Cell Mol Biol"},{"key":"4044_CR18","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5505\/ejm.2019.48658","volume":"24","author":"H Demirkiran","year":"2019","unstructured":"Demirkiran H, Senoglu N, Oksuz H et al (2019) The effects of different doses of ketamine on renal ischemia\/reperfusion injury in rats. Eastern J Med 24:194\u2013199. https:\/\/doi.org\/10.5505\/ejm.2019.48658","journal-title":"Eastern J Med"},{"key":"4044_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/20961790.2017.1285219","volume":"2","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira RJ (2017) Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res 2:2\u201310. https:\/\/doi.org\/10.1080\/20961790.2017.1285219","journal-title":"Forensic Sci Res"},{"key":"4044_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2014.00361","author":"LN Diogo","year":"2014","unstructured":"Diogo LN, Monteiro EC (2014) The efficacy of antihypertensive drugs in chronic intermittent hypoxia conditions. Front Physiol. https:\/\/doi.org\/10.3389\/FPHYS.2014.00361","journal-title":"Front Physiol"},{"key":"4044_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.EJPHAR.2015.08.019","volume":"765","author":"LN Diogo","year":"2015","unstructured":"Diogo LN, Pereira SA, Nunes AR et al (2015) Efficacy of carvedilol in reversing hypertension induced by chronic intermittent hypoxia in rats. Eur J Pharmacol 765:58\u201367. https:\/\/doi.org\/10.1016\/J.EJPHAR.2015.08.019","journal-title":"Eur J Pharmacol"},{"key":"4044_CR22","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0024-3205(01)01287-5","volume":"69","author":"SR Edwards","year":"2001","unstructured":"Edwards SR, Mather LE (2001) Tissue uptake of ketamine and norketamine enantiomers in the rat: indirect evidence for extrahepatic metabolic inversion. Life Sci 69:2051\u20132066. https:\/\/doi.org\/10.1016\/S0024-3205(01)01287-5","journal-title":"Life Sci"},{"key":"4044_CR23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1124\/DMD.30.7.853","volume":"30","author":"Y Hijazi","year":"2002","unstructured":"Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853\u2013858. https:\/\/doi.org\/10.1124\/DMD.30.7.853","journal-title":"Drug Metab Dispos"},{"key":"4044_CR24","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.3390\/IJMS19082459","volume":"19","author":"CN Hsu","year":"2018","unstructured":"Hsu CN, Lin YJ, Lu PC, Tain YL (2018) Maternal resveratrol therapy protects male rat offspring against programmed hypertension induced by TCDD and dexamethasone exposures: is it relevant to aryl hydrocarbon receptor? Int J Mol Sci 19:2459. https:\/\/doi.org\/10.3390\/IJMS19082459","journal-title":"Int J Mol Sci"},{"key":"4044_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/GLIA.24326","volume":"71","author":"YJ Huang","year":"2023","unstructured":"Huang YJ, Hung CC, Hsu PC et al (2023) Astrocytic aryl hydrocarbon receptor mediates chronic kidney disease-associated mental disorders involving GLT1 hypofunction and neuronal activity enhancement in the mouse brain. Glia 71:1057\u20131080. https:\/\/doi.org\/10.1002\/GLIA.24326","journal-title":"Glia"},{"key":"4044_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJPS.2024.106735","volume":"198","author":"H Kahma","year":"2024","unstructured":"Kahma H, Paludetto MN, Neuvonen M et al (2024) Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes\u2014detailed studies on CYP3A inhibitors. Eur J Pharm Sci 198:106735. https:\/\/doi.org\/10.1016\/J.EJPS.2024.106735","journal-title":"Eur J Pharm Sci"},{"key":"4044_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/BIOINFORMATICS\/BTK039","volume":"22","author":"M Katajamaa","year":"2006","unstructured":"Katajamaa M, Miettinen J, Ore\u0161i\u010d M (2006) MZmine: toolbox for processing and visualization of mass spectrometry based molecular profile data. Bioinformatics 22:634\u2013636. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTK039","journal-title":"Bioinformatics"},{"key":"4044_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000139276","volume":"50","author":"JM Loch","year":"1995","unstructured":"Loch JM, Potter J, Bachmann KA (1995) The influence of anesthetic agents on rat hepatic cytochromes P450 in vivo. Pharmacology 50:146\u2013153. https:\/\/doi.org\/10.1159\/000139276","journal-title":"Pharmacology"},{"key":"4044_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1124\/DMD.31.4.421","volume":"31","author":"A Madan","year":"2003","unstructured":"Madan A, Graham RA, Carroll KM et al (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421\u2013431. https:\/\/doi.org\/10.1124\/DMD.31.4.421","journal-title":"Drug Metab Dispos"},{"key":"4044_CR30","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/CNS.12099","volume":"19","author":"G Mion","year":"2013","unstructured":"Mion G, Villevieille T (2013) Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19:370\u2013380. https:\/\/doi.org\/10.1111\/CNS.12099","journal-title":"CNS Neurosci Ther"},{"key":"4044_CR31","doi-asserted-by":"publisher","first-page":"F635","DOI":"10.1152\/AJPRENAL.00254.2018","volume":"316","author":"J O\u2019Neill","year":"2019","unstructured":"O\u2019Neill J, Jasionek G, Drummond SE et al (2019) Renal cortical oxygen tension is decreased following exposure to long-term but not short-term intermittent hypoxia in the rat. Am J Physiol Renal Physiol 316:F635\u2013F645. https:\/\/doi.org\/10.1152\/AJPRENAL.00254.2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"4044_CR32","doi-asserted-by":"publisher","first-page":"7260","DOI":"10.3390\/IJERPH17197260","volume":"17","author":"SH Ou","year":"2020","unstructured":"Ou SH, Wu LY, Chen HY et al (2020) Risk of renal function decline in patients with ketamine-associated uropathy. Int J Environ Res Public Health 17:7260. https:\/\/doi.org\/10.3390\/IJERPH17197260","journal-title":"Int J Environ Res Public Health"},{"key":"4044_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-031-32371-3_4","volume":"1427","author":"AB Pimp\u00e3o","year":"2023","unstructured":"Pimp\u00e3o AB, Sousa C, Correia MJ et al (2023) Control of arterial hypertension by the AhR blocker CH-223191: a chronopharmacological study in chronic intermittent hypoxia conditions. Adv Exp Med Biol 1427:35\u201342. https:\/\/doi.org\/10.1007\/978-3-031-32371-3_4","journal-title":"Adv Exp Med Biol"},{"key":"4044_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2105-11-395\/TABLES\/3","volume":"11","author":"T Pluskal","year":"2010","unstructured":"Pluskal T, Castillo S, Villar-Briones A, Ore\u0161i\u010d M (2010) MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 11:1\u201311. https:\/\/doi.org\/10.1186\/1471-2105-11-395\/TABLES\/3","journal-title":"BMC Bioinformatics"},{"issue":"6","key":"4044_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","volume":"176","author":"V Popova","year":"2019","unstructured":"Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB (2019) Efficacy and safety of flexibly dosed Esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 176(6):428\u2013438. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19020172","journal-title":"Am J Psychiatry"},{"key":"4044_CR35","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1161\/CIRCULATIONAHA.105.556746","volume":"112","author":"S Ryan","year":"2005","unstructured":"Ryan S, Taylor CT, McNicholas WT (2005) Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112:2660\u20132667. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.556746","journal-title":"Circulation"},{"key":"4044_CR36","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/AAP.0000000000000806","volume":"43","author":"ES Schwenk","year":"2018","unstructured":"Schwenk ES, Viscusi ER, Buvanendran A et al (2018) Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 43:456\u2013466. https:\/\/doi.org\/10.1097\/AAP.0000000000000806","journal-title":"Reg Anesth Pain Med"},{"key":"4044_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1124\/JPET.115.230755\/ATTACHMENT\/E014ED56-1363-4993-9470-3F23D2D96056\/MMC1_SUPP_FIG1.PDF","volume":"357","author":"RJ Scialis","year":"2016","unstructured":"Scialis RJ, Manautou JE (2016) Elucidation of the mechanisms through which the reactive metabolite diclofenac acyl glucuronide can mediate toxicity. J Pharmacol Exp Ther 357:167\u2013176. https:\/\/doi.org\/10.1124\/JPET.115.230755\/ATTACHMENT\/E014ED56-1363-4993-9470-3F23D2D96056\/MMC1_SUPP_FIG1.PDF","journal-title":"J Pharmacol Exp Ther"},{"key":"4044_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/S41536-023-00339-7","volume":"8","author":"J Shen","year":"2023","unstructured":"Shen J, Wang Y, Zheng F et al (2023) Aryl hydrocarbon receptor regulates IL-22 receptor expression on thymic epithelial cell and accelerates thymus regeneration. NPJ Regen Med 8:64. https:\/\/doi.org\/10.1038\/S41536-023-00339-7","journal-title":"NPJ Regen Med"},{"key":"4044_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1124\/JPET.104.068536","volume":"311","author":"Y Shitara","year":"2004","unstructured":"Shitara Y, Hirano M, Sato H, Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2\/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228\u2013236. https:\/\/doi.org\/10.1124\/JPET.104.068536","journal-title":"J Pharmacol Exp Ther"},{"key":"4044_CR40","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1021\/AC051437Y","volume":"78","author":"CA Smith","year":"2006","unstructured":"Smith CA, Want EJ, O\u2019Maille G et al (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78:779\u2013787. https:\/\/doi.org\/10.1021\/AC051437Y","journal-title":"Anal Chem"},{"key":"4044_CR41","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/1471-2105-9-504","volume":"9","author":"R Tautenhahn","year":"2008","unstructured":"Tautenhahn R, Bottcher C, Neumann S (2008) Highly sensitive feature detection for high resolution LC\/MS. BMC Bioinformatics 9:504. https:\/\/doi.org\/10.1186\/1471-2105-9-504","journal-title":"BMC Bioinformatics"},{"key":"4044_CR42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/CLPT.2014.141","volume":"96","author":"A Tornio","year":"2014","unstructured":"Tornio A, Filppula AM, Kailari O et al (2014) Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 96:498\u2013507. https:\/\/doi.org\/10.1038\/CLPT.2014.141","journal-title":"Clin Pharmacol Ther"},{"key":"4044_CR43","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1124\/DMD.108.026328","volume":"37","author":"SC Turfus","year":"2009","unstructured":"Turfus SC, Parkin MC, Cowan DA et al (2009) Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 37:1778. https:\/\/doi.org\/10.1124\/DMD.108.026328","journal-title":"Drug Metab Dispos"},{"key":"4044_CR44","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1021\/acschemneuro.4c00051","volume":"15","author":"T Vallianatou","year":"2024","unstructured":"Vallianatou T, de Souza AC, Tsiara I et al (2024) Identification of new ketamine metabolites and their detailed distribution in the mammalian brain. ACS Chem Neurosci 15:1335\u20131341. https:\/\/doi.org\/10.1021\/acschemneuro.4c00051","journal-title":"ACS Chem Neurosci"},{"key":"4044_CR45","first-page":"77","volume":"13","author":"BM VandenBrink","year":"2010","unstructured":"VandenBrink BM, Isoherranen N (2010) The role of metabolites in predicting drug-drug interactions: focus on irreversible P450 inhibition. Curr Opin Drug Discov Devel 13:77","journal-title":"Curr Opin Drug Discov Devel"},{"key":"4044_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/00000542-198202000-00007","volume":"56","author":"PF White","year":"1982","unstructured":"White PF, Way WL, Trevor AJ (1982) Ketamine\u2013its pharmacology and therapeutic uses. Anesthesiology 56:119\u2013136. https:\/\/doi.org\/10.1097\/00000542-198202000-00007","journal-title":"Anesthesiology"},{"key":"4044_CR47","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/TOXSCI\/KFP115","volume":"111","author":"RL Yeager","year":"2009","unstructured":"Yeager RL, Reisman SA, Aleksunes LM, Klaassen CD (2009) Introducing the \u201cTCDD-inducible AhR-Nrf2 gene battery.\u201d Toxicol Sci 111:238\u2013246. https:\/\/doi.org\/10.1093\/TOXSCI\/KFP115","journal-title":"Toxicol Sci"},{"key":"4044_CR48","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1161\/CIR.0000000000000988","volume":"144","author":"Y Yeghiazarians","year":"2021","unstructured":"Yeghiazarians Y, Jneid H, Tietjens JR et al (2021) Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 144:E56\u2013E67. https:\/\/doi.org\/10.1161\/CIR.0000000000000988","journal-title":"Circulation"},{"key":"4044_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0006-2952(97)00476-0","volume":"55","author":"H Zaher","year":"1998","unstructured":"Zaher H, Yang TJ, Gelboin HV et al (1998) Effect of phenobarbital on hepatic CYP1A1 and CYP1A2 in the Ahr-null mouse. Biochem Pharmacol 55:235\u2013238. https:\/\/doi.org\/10.1016\/S0006-2952(97)00476-0","journal-title":"Biochem Pharmacol"},{"key":"4044_CR50","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1124\/PR.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ et al (2018) Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev 70:660. https:\/\/doi.org\/10.1124\/PR.117.015198","journal-title":"Pharmacol Rev"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-04044-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-025-04044-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-025-04044-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T13:52:12Z","timestamp":1750859532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-025-04044-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["4044"],"URL":"https:\/\/doi.org\/10.1007\/s00204-025-04044-w","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"type":"print","value":"0340-5761"},{"type":"electronic","value":"1432-0738"}],"subject":[],"published":{"date-parts":[[2025,4,19]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All applicable institutional and governmental regulations concerning the ethical use of animals were followed, according to the NIH Principles of Laboratory Animal Care (NIH Publication 85-23, revised 1985), the European guidelines for the protection of animals used for scientific purposes (European Union Directive 2010\/63\/EU), and Portuguese Law n\u00ba 113\/2013. The Ethical Committee of NOVA Medical School approved all experimental procedures (protocol n\u00ba 15\/2017\/CEFCM).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}